CD274 and neoplasm: Studies with nivolumab or atezolizumab were conducted regardless of PD-L1 expression (CheckMate-017 study, CheckMate-057 study, OAK study [118–120]), while a study of pembrolizumab was conducted only in patients whose tumor expressed PD-L1 > 1% (KEYNOTE-010 study [121]).